Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

harmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect the company's current views regarding the potential of the company's technology platforms, the tablet formulation of NKTR-118, and the scientific and commercial potential of NKTR-118 and the results of the Phase 2 study for that drug candidate. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) NKTR-118 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage prior to regulatory approval due to efficacy, safety or other factors; (ii) the timing or success of the commencemen
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will present at the 16th Annual B. Riley ... 13, 2015. The conference will be held May 12-14, 2015 ... Heska management will be available during the day on ...
(Date:5/1/2015)... , May 1, 2015 At the ... 2-6 in Washington D.C. , Elekta ... solution that enables clinicians to leverage the enormous amount ... radiosurgery treatments conducted each year – to advance clinical ... Knife Registry is a cloud-based solution that allows practitioners ...
(Date:5/1/2015)... 1, 2015 Braeburn Pharmaceuticals announced ... therapeutic focus beyond addiction and pain to ... Braeburn has acquired an implantable, six-month formulation ... for treatment of schizophrenia from Endo Pharmaceuticals. ... rights to other potential applications of the ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4
... SAN DIEGO, Oct. 28 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... 30, 2009. For the third quarter of 2009, the Company reported ... with a net loss of $17.7 million, or $0.46 per share, ... September 30, 2009, the Company reported a net loss of $43.1 ...
... BATESVILLE, Ind., Oct. 28 Hill-Rom Holdings, Inc. (NYSE: ... and 2010 financial guidance on Wednesday, November 11, 2009. ... morning on Thursday, November 12, 2009 at 7:30 a.m. EST. ... Quarter Earnings and 2010 Financial Guidance release will be issued ...
Cached Medicine Technology:Neurocrine Biosciences Reports Third Quarter 2009 Results 2Neurocrine Biosciences Reports Third Quarter 2009 Results 3Neurocrine Biosciences Reports Third Quarter 2009 Results 4Neurocrine Biosciences Reports Third Quarter 2009 Results 5Neurocrine Biosciences Reports Third Quarter 2009 Results 6Neurocrine Biosciences Reports Third Quarter 2009 Results 7Neurocrine Biosciences Reports Third Quarter 2009 Results 8Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 2
(Date:5/1/2015)... 2015 It’s raining bills on Capitol Hill ... to expand federal support for telemedicine. , “Such ... been working with Congress,” said Jonathan Linkous, CEO of the ... nation is poised to embrace the use of telecommunications in ... in fulfilling ATA’s mission to improve quality, access, equity and ...
(Date:5/1/2015)... May 01, 2015 Ernst & Young ... Joshua Rosenthal, Co-Founder & CSO, and Burak Sezen, Co-Founder ... the EY Entrepreneur Of The Year® 2015 Awards ... Young is a global leader in assurance, tax, ... be one of the top audit companies in the ...
(Date:5/1/2015)... The Quail Creek Relay for Life Team raised over $89,000 ... Creek Relay team has raised almost $860,000. Quail Creek ... their biggest event, January’s Dinner and Auction; an annual Putting ... Relay for Life team was established to honor a member’s ... “I was hooked when I learned how the money raised ...
(Date:5/1/2015)... As the sale of legal, recreational cannabis ... people in the industry are looking back with some ... annual report by the ArcView Group , the ... reached nearly $3 billion in combined wholesale and retail ... combined with the ongoing economic recovery, has led to ...
(Date:5/1/2015)... The frozen yogurt chain sweetFrog Enterprises is ... and the Myrtle Beach Pellicans (SC). As part of ... offer fans discounts at local sweetFrog locations. , “We ... Luke Shook, co-owner of the Hickory sweetFrog. “Sponsoring ... forward to enjoying the games and the great taste ...
Breaking Medicine News(10 mins):Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3Health News:sweetFrog Announces Minor League Baseball Partnerships 2
... strategy to hunt for human viruses described in this ... team who found the cause of Kaposis sarcoma has ... rare but deadly skin cancer called Merkel cell carcinoma. ... researchers, Huichen Feng, Ph.D., Masahiro Shuda, Ph.D., Yuan Chang, ...
... better treatments, researchers say , , THURSDAY, Jan. 17 (HealthDay News) ... twins, scientists say they,re gaining new insight into how some ... The researchers report in a new study that both twins ... shared cells that mutated and became precancerous. In one of ...
... Bionic Woman use bionic eyes to zoom in on far-off ... or create virtual crosshairs. Off the screen, virtual displays have ... help vision-impaired people, holographic driving control panels and even as ... , The device to make this happen may be familiar. ...
... ATLANTA, Jan. 17 Fundraising for two of,Atlanta,s ... Atlanta Mayor Shirley Franklin and Wachovia,s Atlanta ... to the Atlanta BeltLine,Partnership and the Center for ... Foundation. The gifts will go toward each initiative,s,capital ...
... FOREST, Ill., Jan. 17 Hospira, Inc.,(NYSE: HSP ... it will host a conference call to discuss its ... Thursday, Feb. 28, 2008,at 8 a.m. Central Time., ... results,earlier that morning, before the U.S. stock market open ...
... officials are constantly in battle mode against illness ... to fight these deadly foes they need more ... Researchers from the Regenstrief Institute and the Indiana ... electronic medical laboratory reporting (ELR) improves both the ...
Cached Medicine News:Health News:Newly discovered virus linked to deadly skin cancer 2Health News:Newly discovered virus linked to deadly skin cancer 3Health News:Newly discovered virus linked to deadly skin cancer 4Health News:Study Gets Closer to Origins of Leukemia 2Health News:Contact lenses with circuits, lights a possible platform for superhuman vision 2Health News:Contact lenses with circuits, lights a possible platform for superhuman vision 3Health News:Wachovia Foundation Announces $1 Million Each for Atlanta BeltLine Partnership, Center for Civil and Human Rights 2Health News:Wachovia Foundation Announces $1 Million Each for Atlanta BeltLine Partnership, Center for Civil and Human Rights 3Health News:Battling potential disease outbreaks online 2
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
... 5500TM is the worlds first spot ... and heart rate to use reflectance ... uses SPO Medicals patented technology to ... more usable for many patients and ...
All-in-One Fingertip Oximeter...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: